President’s Message

Dear Members and Friends of the Society,

It is perhaps an understatement to say that we are living in extraordinary times, one that we had not prepared for, and as I write to you today, my first hope is that you and your family are safe and well. It is in such times of crisis that the true character of people becomes known, and I have been inspired (but not entirely surprised) by the strength and compassion of our membership in the face of this pandemic. I believe that strength of character, courage and care for one another will get us through these remarkably challenging times. I would be remiss if I do not give special recognition to the patients we serve, who have remained resilient in the face of such unprecedented times, teaching us the strength and resolution in their will to face and live with the diagnoses of brain tumors with the many challenges and uncertainties of the pandemic.

There is a silver lining in all we experience in life, and having not anticipated to be leading the Society through a pandemic, the silver lining is to witness the strong fabric of the Society members, the commitment and dedication of all SNO officers, leadership and the broader community to continue to stay focused on the mission and goals of the society. It is a unique opportunity to take advantage of the unintended positive

As the global medical community and the world come together to face the challenges of COVID-19, the Society for Neuro-Oncology established a COVID Task Force to address the needs of the Society’s membership and the neuro-oncology community. The Task Force’s mandate is to identify, develop, and disseminate guidance and educational resources specific to COVID-19 and the treatment and research of brain tumors.

The camaraderie and collaborative spirit that this working group has demonstrated is truly a testament to the quality and compassion of the SNO membership.

Below we are pleased to share with you a summary of the activities of the Task Force to-date.

**SNO COVID-19 Resource Page**

Task Force members submitted links, resources and content for the COVID-19 page on the SNO website, found here. We will continue to share relevant information as necessary and update the page frequently.

**IBTA Patient & Caregiver Survey**

SNO was pleased to collaborate with the International Brain Tumour Alliance (IBTA) on a patient and caregiver survey. Translated into six languages, the response from the advocacy community was significant, with over 1500 submissions. A manuscript is currently being prepared for publication.

**Neuro-Oncology Provider Survey**

With the assistance of sister neuro-oncology societies from around the world, the COVID-19 survey for healthcare professionals received close to 600 responses, a new record for a professional SNO survey. The responses are currently being analyzed with the help of statistician Quinn Ostrom and will be published in one of SNO’s journals, and discussed during a special session during the Annual Meeting. We would like to thank Milan Chheda, Maciej Mrugala, Shelley Pressley and the entire Task Force team for contributing to the survey.

**COVID-19 and the Brain Tumor Community Webinar**

Broadcast live on April 22, Susan Bell, Susan Chang, Rohan Ramakrishna, Erik Sulman, and Kathy Oliver engaged in spirited and timely discussion on the impact of the pandemic on the neuro-oncology community. The webinar can be viewed here.

**Patient and Caregiver Fact Sheet**

Brain tumor patients are already dealing with distress and uncertainty, and the pandemic
President’s Message, continued.

consequences of the pandemic to steer the Society in directions we have not to date explored or envisioned.

I am humbled and grateful to the many members who have contributed to our special COVID-19 resource page. As you will read further in this newsletter, this special section of the SNO website is updated frequently with new content, and was collaboratively developed by a range of SNO committees.

The viability of an in-person Annual Meeting – the educational highlight of our year -- remains a concern. At this point, all contingencies are being considered for our November event. I am grateful for the advice and counsel of the SNO officers, Chas Haynes, Tracy Batchelor, and Erik Sulman, as we together explore a myriad of options with the City of Austin and other key stakeholders. My hope is that we will have a clearer understanding of what lies ahead in early August, but rest assured, one way or another, we are planning to deliver the exceptional educational content that SNO is known for in November. Serving as a Chair of the Annual Meeting is a massive undertaking under any circumstances, so this year has been exceptionally complex and demanding. I would like to recognize the tremendous work of the main meeting Co-Chairs Monika Hegi, Michael Lim, Farshad Nassiri and David Schiff, who have together spent countless hours with the SNO administrative staff (Angie Ames, Linda Greer, Megan Johnston, Tara Mammoser, Shelley Pressley, and Ginger Vazquez) to plan and organize the meeting. I would also like to thank Daniel De Carvalho, Houtan Noushmehr, and Susan Short for their efforts to organize the Biomarker component to Education Day, and also Sue Bell, Sandra Johnston, and Maureen Daniels for organizing an exceptional Allied Health/Survivorship session. In an effort to include as many members as possible in the planning of the meeting, this year for the first time we invited members to submit their ideas for pre-meeting courses. We received an excellent response to our call for proposals, and I would like to thank Albert Kim and Kyle Walsh for participating in the review and selection process for these courses.

After considerable thought, we have had to make the difficult -- but necessary -- decision to postpone the SNO 2nd Annual Conference on Brain Metastases, held in association with the Section on Tumors of the AANS/CNS, to 2021. For the safety of our membership I am grateful for the advice and counsel of the SNO officers, Chas Haynes, Tracy Batchelor, and Erik Sulman, as we together explore a myriad of options with the City of Austin and other key stakeholders. My hope is that we will have a clearer understanding of what lies ahead in early August, but rest assured, one way or another, we are planning to deliver the exceptional educational content that SNO is known for in November.

As we cope with and try to define the new normal, SNO has been exploring new ways to engage and provide value to our membership. I would like to thank Patrick Wen and Isabel Arrillaga-Romany for leading the SNO Education Committee, which is responsible for the development and dissemination of non-meeting related education via our website. They have already organized a series of very well-attended webinars, including Primary CNS Lymphoma: An Update on Diagnosis and Management by Tracy Batchelor, cIMPACT and Other Brain Tumor Classification Updates by David Louis, Understanding Molecular Characteristics of Tumors and Implications for Treatment by Craig Horbinski, Lower-Grade Gliomas by David Schiff, and numerous other webinars are in the works. I would also like to acknowledge the work of David Gutmann and Roger Packer, who chaired an enduring CME activity on the Future Treatment Paradigm of NF1. All of these educational offerings can be found here.

While we may be limited in our ability to share information face-to-face, I am thrilled to report that our three official journals are flourishing. The latest impact factor for our flagship publication, Neuro-Oncology, has risen once again, to 10.247, increasing from 2018’s 10.091. Congratulations to both past Editor-in-Chief Patrick Wen, and current Editor-in-Chief Kenneth Aldape, whose efforts contributed to this increase. I would like especially thank Susan Chang for her successful tenure as the founding Editor-in-Chief of our second journal, Neuro-Oncology Practice (NOP). This journal has filled a vital gap in the neuro-oncology literature, publishing important papers on the applied and practical aspects of treating patients in our field. The journal has gone from quarterly to bi-monthly publication, and is now fully discoverable in PubMed. With NOP now firmly established as an important resource for our community, Susan is handing off the editorial leadership of the journal to our partners at the European Association of Neuro-Oncology, and as you will read in this newsletter, Martin Taphoorn will assume the role of Editor-in-Chief for seven years starting in January of 2021. I am also pleased to report

register at no charge, click here.

Similarly, the Joint SNO/NIH Conference on Targeting CNS Tumor Metabolism has also been moved, and will now take place April 6-7, 2021. This important conference seeks to bring together clinicians and experts in tumor metabolism in order to increase the utilization of metabolic investigations in clinical settings. Co-Chairs Mioara Larion and Elizabeth Maher have assembled an impressive contingent of invited speakers including Craig Thompson, Paul Mischel, Daniel Cahill, Sabrina Ronen, Ovidiu Andronisei, Christian Metallo, and Houtan Noushmehr. The new abstract submission deadline is December 1, 2020. Members can learn more about the conference and can submit their research by clicking here.

Continued on page 3
that our new open access journal, Neuro-Oncology Advances (NOA) is now fully searchable in PubMed, and all articles published to-date in NOA are retroactively discoverable. Finally on the journal front, a supplement on Neurofibromatosis has just been released in NOA, and members can claim four hours of complimentary CME credits after reading the issue. Many leaders in the field of NF contributed to this special edition, and we are grateful to these authors. I would like to thank Suganth Suppiah for his hard work to make this special CME issue possible!

I am pleased to announce that building on the tremendous success of Women in Neuro-Oncology Committee, we have created a new SNO committee, the Women and Diversity Committee, led by Ugonna Chukwueke, Shawn Hervey-Jumper, and continuing on in this expanded role, Alyx Porter. The new committee seeks to advance the careers of women and underrepresented SNO members through engagement, research, and clinical care. You can learn more about the Women and Diversity Committee further in this newsletter.

Lastly, I am mindful that this a stressful and anxious time for our entire community. The wellness and mental health of our members must not be overlooked, so I greatly appreciate the efforts of Terri Armstrong and Alvina Acquaye of the SNO Wellness Committee who facilitated an excellent webinar entitled This Pandemic Isn’t Making My Burnout Better: A Systematic Approach to Coping During Covid-19 featuring internationally recognized burnout expert, Dan Shapiro. I would urge all SNO members to view this enlightening webinar.

Certainly this is not the year that any of us anticipated, but I am sincerely grateful to the SNO board, committee leadership, track chairs, administrative staff and all of our members around the world, who are working so hard to advance the mission of our Society during this extraordinary time. I am humbled to be entrusted with presidency of the premier neuro-oncology society in the world during such a historic time. I hope COVID will be well behind us soon and we can adopt the positive learnings we have had from this experience to build on resiliency, individually and as a community, so that as a Society we are even stronger and better prepared to help serve our patients.

Gelareh Zadeh, MD
SNO President

Public Policy Committee Update

The SNO Public Policy Committee addresses legislative, regulatory and advocacy issues that may impact or be of interest to the SNO membership. The Public Policy Committee ensures that SNO has representation on Capitol Hill so that members of Congress, policymakers and appropriations staff understand SNO’s position on various regulatory issues that impact the field of neuro-oncology.

Appropriations for Fiscal Year 2021

The SNO Public Policy Committee continues to advocate for an increase in federal funding for the National Institutes of Health and the National Cancer Institute. A successful advocacy process in Fiscal Year 2020 brought large increases to both entities, benefiting the health and well-being of brain cancer patients across the United States. The SNO Public Policy Committee was also successful in working with Congress to secure binding language to prevent changes to indirect costs calculations for NIH grants.

Drug Pricing and Drug Price Gouging

Throughout the 116th Congress, both Democrats and Republicans have put a major focus on legislation to keep drug prices down and to prevent price gouging by pharmaceutical companies. Thus far, no specific proposal has been signed by the President as the parties continue to negotiate. SNO is continuing to work alongside committees of jurisdiction to provide the neuro-oncology community perspective.

COVID-19 Response and Stimulus Packages

The COVID-19 response legislation directly impacts hospitals and healthcare providers. Many have lost revenue due to the suspension of elective surgical procedures and the delay of other medical needs. The SNO Public Policy Committee is working to educate Congress on the impacts of COVID-19 for our members and how Congress can work to best support researchers and hospitals moving forward.

A new section of the SNO website has now been specifically dedicated to public policy matters. In this new section you will find:

- **Action Resources** — Tools to learn more about public policy efforts and get involved.
- **Healthcare Policy Press** — Recent media coverage of policy issues impacting SNO’s membership.
- **Committee Action Items** — Read about the work of the SNO’s Public Policy Committee.
- **Monthly Legislative Update** — Regular updates on priority issues and progress.

To view the Public Policy section of the SNO website, [click here](#).
is of course adding to these concerns. Erin Dunbar, Alireza Mansouri, and Jennie Taylor collaborated to create a fact sheet to provide information specific to brain tumor patients, caregivers and advocates. Please share this resources with your patients! The Patient and Caregiver Fact Sheet is a pdf that can be downloaded from the SNO COVID-19 Resource Page.

**COVID-19 Abstract Category**

The scientific chairs of the 2020 Annual SNO Meeting, Monika Hegi, Michael Lim, David Schiff and Farshad Nassiri, have added a new abstract submission category for SNO2020 so members can share their experiences and learnings during the pandemic. Additional COVID-19 sessions are also being planned to take place during the Annual Meeting.

**Virtual Content at the Annual Meeting**

Ultimately, the health and safety of our registrants, partners, and SNO staff remain our main concern, so we are exploring options to deliver the content of the 2020 SNO Annual Meeting virtually should that become necessary. SNO will devote sessions to mitigating the impact of COVID on our members, as well as delivering the best possible care to patients during the pandemic.

The Society is appreciative of the work the Task Force has done to help address the needs of our membership during this difficult time. We welcome the participation and ideas of all members so that we can meet the academic, professional and personal challenges we will face in the weeks and months ahead. Thanks to your efforts, we have no doubt that we will emerge as a stronger Society when the pandemic is ultimately behind us!

---

**Wellness Webinar: This Pandemic Isn’t Making My Burnout Better - A Systematic Approach to Coping During Covid-19**

Thanks to the efforts of the SNO Wellness Committee, SNO organized a free webinar that addressed burnout and stress mitigation during the COVID-19 pandemic.

Moderated by Wellness Committee Co-Chair Alvina Acquaye, the webinar featured Dr. Daniel Shapiro, an internationally recognized expert in burnout who shared practical strategies for assessing and ameliorating burnout and stress during this difficult time. The webinar originally aired on June 3rd, but members are encouraged to view the archived webinar by clicking here.

---

**COVID-19 Task Force**

SNO thanks all those who contributed to this important initiative.

- Alvina Acquaye
- Sameer Agnihotri
- Terri Armstrong
- Nicholas Butowski
- Susan Chang
- Milan Chheda
- Scott Covin
- Erin Dunbar
- Chas Haynes
- Monika Hegi
- Shawn Hervey-Jumper
- Michael Lim
- Alireza Mansouri
- Maciej Mrugala
- Farshad Nassiri
- Kathy Oliver
- Quinn Ostrom
- Katherine Peters
- Alyx Porter
- Shelley Pressley
- Joanne Salcido
- David Schiff
- Erik Sulman
- Jennie Taylor
- Alissa Thomas
- Martin van den Bent
- Jeffrey Wefel
- Gelareh Zadeh

**SNO Guidance on COVID-19**

If you are interested in joining the Task Force, please contact shelley@soc-neuro-onc.org.
SNO, in association with the AANS/CNS Section on Tumors, is pleased to announce that the 2020 Virtual Conference on Brain Metastases will take place on August 14, from 10am-3pm, Central time. This live event will feature select abstract presentations and invited lectures from the originally scheduled in-person meeting which was set to take place in Toronto in August.

Invited Talks

FDA Recommendations Regarding Efficacy Endpoints and Expanding Eligibility Criteria in Clinical Trials for Patients with Brain Metastases
Amy Barone

Genetic Evolution of Brain Metastases: Implications for Precision Medicine
Priscilla Brastianos

NCIC CE7 - An Update on the Treatment of Multiple Brain Metastases
David Roberge

Surgery for Brain Metastases; Past, Present and Future Perspectives
Raymond Sawaya

Advances in Animal Models in Brain Metastases
Manuel Valiente

Additional Educational Content

In addition to the invited talks, the live portion of the conference will feature nine top scoring presentations from the submitted abstracts. There will also be pre-recorded oral abstract presentations and electronic poster presentations available on-demand. All of the educational material will be accessible for viewing after the conference has concluded through the SNO Education Center.

Scientific Program Co-Chairs

- Priscilla Brastianos, Massachusetts General Hospital
- Paul Kongkham, Toronto Western Hospital, University Health Network
- David Shultz, Princess Margaret Cancer Center
- Rohan Ramakrishna, Weill Cornell Medicine (AANS/CNS Section on Tumors Representative)

Registration Information

To view the live program, click here.
To register for the program at no charge, click here.
Women and Diversity Committee Update

Building on successful initiatives from Women in Neuro-Oncology (WIN), the decision was made to broaden the scope by officially renaming the committee as the Women and Diversity Committee. The primary mission of the Women and Diversity Committee is to advance the careers of women and underrepresented SNO members through engagement, research, and clinical care. On March 27, 2020, seventy-seven SNO members attended the committee’s initial meeting, after which working groups were established.

Engagement

One of the efforts developed to advance the careers of SNO members who are women and underrepresented in medicine (URM) junior faculty is a 6-month facilitated peer mentorship pilot to begin late summer. This pilot was developed in response to a survey conducted by WiN in 2019 that revealed 43% of respondents identified ineffective mentorship as a barrier to their career development. Through this pilot, participants will have the opportunity to network and learn from other SNO members as part of their cohort in addition to participating in activities and having access to resources to assist with their professional development. If this pilot is successful, we propose offering on a larger scale to SNO members.

Research

Understanding the unique needs and perspectives of our diverse North American and International membership remains a top priority. Research efforts in WDC have therefore centered on the creation of a SNO diversity survey. Led by Dr Sadhana Jackson, this survey will provide metrics and insight in the unique needs of SNO membership with the goal of using these data towards program development. To take the survey, click here.

Clinical Care

Within this clinical care subcommittee, a major initiative has been in development of strategies to improve enrollment of underserved brain tumor patients to clinical trials. This group is developing a clinical trials “roadmap”, addressing factors including but not limited to patient, provider and institutional challenges to enrollment of vulnerable peoples. Through the working groups, membership and community-facing events are planned to raise understanding of various aspects of clinical trials as well as unique issues affecting women and diverse populations.

Working Groups

You are encouraged to be part of a working group. Your expertise and investment are essential! If you are interested in participating in any of the working groups listed below, please contact the working group leader.

Women in Neuro-Oncology is led by Dr Peters. The mission of this working group is to advance the careers of women in neuro-oncology. katherine.peters@duke.edu.

Mentorship and Networking is led by Dr. Porter. The mission of this working group is to establish tools for connections and collaboration within neuro-oncology. Porter.Alyx@mayo.edu.

Abstract and Travel Scholarships is led by Dr. Hervey-Jumper. The mission of this working group is to secure funds and partner with the awards committee in the selection of women and underrepresented in medicine trainees for travel scholarships to the annual meeting. Shawn.Hervey-Jumper@ucsf.edu.

Investigator Diversity is led by Dr. Hervey-Jumper. The mission of this working group is to work with funding agencies to promote and advertise funding opportunities for minority investigators. Shawn.Hervey-Jumper@ucsf.edu.

Clinical Trial Enrollment is led by Dr. Chukwueke. The mission of this working group is to develop strategies to enhance minority enrollment in clinical trials. Ugonma_Chukwueke@dfci.harvard.edu.

Neuro-Oncologic Considerations in Women and Diverse Populations is led by Dr. Gatson. The mission of this working group is to share and commission research focused on women’s issues and minority health including annual meeting education sessions. Ngatson@geisinger.edu.

Community Outreach is led by Dr. de la Fuente. This working group will organize community outreach lectures that coincides with the annual meeting. mdelafuente@med.miami.edu.

To join the Women and Diversity Committee, indicate your interest by ticking the box on your new SNO member application or during renewal. The next large group committee meeting will be Fall 2020. For additional information, click here.
The SNO-NCI Joint Symposium: “Targeting CNS Tumor Metabolism” will foster collaboration and scientific exchange in the area of metabolism to positively influence outcomes for patients with CNS cancers.

This will be the first conference that focuses specifically on tumor metabolism and it is expected to provide both a didactic as well as collegial learning environment with the goal of enhancing partnerships and advancing new treatments for patients. Metabolic investigations for these tumors have been conducted in isolation and this meeting seeks to bring together clinicians with the experts in metabolism in order to increase the utilization of metabolic investigations in the clinical setting.

Participants will gain new understanding of CNS tumor metabolism via the use of state-of-the-art techniques; the interaction between the metabolism and the other -omics such as epigenomics, transcriptomics, as well as the current standard of care; and the challenges in targeting the metabolic signaling pathways. Topics to be covered over this two-day event include:

- Epigenome, Transcriptome, Metabolome and Modeling
- Metabolic Fluxes and Signaling of Metabolic Pathways
- New Technologies for Studying Brain Metabolism
- Metabolic Biomarkers and Imaging
- Metabolic Drug Targets, Resistance

**Conference Keynotes**

- Paul Mischel
  Distinguished Professor, University of California San Diego
- Craig Thompson
  President and CEO, Memorial Sloan Kettering Cancer Center

**Invited Speakers**

- Daniel Cahill
  Harvard Medical School
- Sabrina Ronen
  Univ. of California, San Francisco
- Ovidiu Andronisei
  Harvard Medical School
- Christian Metallo
  University of California San Diego
- Houtan Noushmehr
  Henry Ford Cancer Institute

**Scientific Program Committee**

- Mioara Larion
  National Institutes of Health (NCI Program Co-Chair)
- Elizabeth Maher
  UT Southwestern Medical Center (SNO Program Co-Chair)
- Mark Gilbert
  National Institutes of Health (NCI Institutional Chair)
- Gelareh Zadeh
  University of Toronto (SNO Institutional Chair)

**Trainee Travel Grants**

Thanks to the generosity of the Dabbiere family, ten trainee travel grants will be available for this meeting. The grant will cover registration, hotel, and $500 to cover travel expenses. To be eligible, recipients must be currently no more than 5 years after obtaining their terminal degree, have an active interest in brain tumor research, and be the first and presenting author on the submitted abstract.

To submit an abstract or to register for this conference, [click here](#).
Neuro-Oncology Impact Factor Increases Again!

The latest Journal Citation Reports (Source Clarivate, 2020) have recently been released and the Society is delighted to share that the latest Impact Factor for Neuro-Oncology has risen to 10.247, increasing from 10.091.

SNO congratulates past Editor-in-Chief Patrick Wen, and current Editor-in-Chief Kenneth Aldape, whose combined efforts contributed to this impressive increase.

The Society also would like to thank the broader SNO membership for contributing to the journal’s success by citing published papers and submitting high-quality research to the journal.

To celebrate the new Impact Factor, the editors have curated a selection of highly cited articles contributing to the increase and invite members to explore this collection.

Neuro-Oncology Advances Celebrates First Year of Publication with Full PubMed Indexing

It has been just over a year since the fully open access journal from SNO and EANO published its inaugural editorial by Editor-in-Chief Gelareh Zadeh.

For the most recent research published in NOA you can access the latest issue here.

It has been a superb first year for the journal, publishing well over 120 papers to-date, with over 60,000 downloads cumulatively.

Several papers have received high engagement online via news outlets, blogs, and Twitter with a large number of papers receiving Altmetric scores.

To find out about the most read and the latest articles, as well as information on submitting your paper to NOA and signing up for new content e-alerts, visit the dedicated journal website.

We are also delighted to announce that Neuro-Oncology Advances is now fully indexed and discoverable via PubMed, providing greater visibility to authors. Additionally, all papers previously published in the journal will be have retrospectively deposited into the PubMed database.

SNO and OUP congratulate the editorial leadership of NOA for an extraordinarily successful inaugural year!

Continuing Medical Education Credit on Neurofibromatosis Available at No Charge

The following enduring CME materials are available to the SNO membership at no charge. These educational activities were supported by an educational grant from AstraZeneca.

Journal Supplement: A Contemporary Landscape of the Clinical and Biological Research in Neurofibromatosis Type 1

Upon completion of this activity, participants should be better able to: Describe the relevance of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors, Interpret efficacy and safety data from the latest clinical trials investigating MEK inhibitors, Describe the molecular drivers for the spectrum of tumors in NF1, Assess the development of potential targeted therapies for the spectrum of tumors in NF1, and Describe the importance of developing new measures of quality of life to facilitate the design of clinical trials in NF1. This activity is designated for 4.0 AMA PRA Category 1 Credits™.

To access this supplement to Neuro-Oncology Advances, click here.

On-Demand Webinar: Will MEK Inhibitors Change the Future Paradigm of Neurofibromatosis Type 1?

The goal of this activity is to improve knowledge related to mitogen-extracellular activated protein kinase kinase (MEK) inhibitors and their role in the treatment of neurofibromatosis type 1 (NF1)-related tumors. The faculty for this education are David H. Gutmann, Washington University School of Medicine, and Roger J. Packer, Children’s National Hospital. This activity is designated for .5 AMA PRA Category 1 Credits™.

To access this content, click here. You will be asked to create an account on the MedScape website.
The Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO) are pleased to announce that the next Editor-in-Chief of Neuro-Oncology Practice will be Martin Taphoorn, Professor of Neuro-Oncology at Leiden University in the Netherlands.

Dr. Taphoorn takes the reigns of Neuro-Oncology Practice from Susan Chang, the Director of the Division of Neuro-Oncology at the University of California, San Francisco. As the founding editor, Dr. Chang has guided Neuro-Oncology Practice since the publication's inception in 2014. During her successful tenure as Editor-in-Chief, the journal has increased in frequency from quarterly to bimonthly publication, and now boasts an impressive average of over 8000 article downloads per month.

Commented Gelareh Zadeh, President of the Society for Neuro-Oncology, “Neuro-Oncology Practice has been an unmitigated success, and we are extremely grateful to Dr. Chang who has done an exceptional job in both launching the journal, and establishing it as one of the leading resources on the subject of CNS malignancies.”

“We are very pleased that Dr. Taphoorn will be leading the journal next year,” added Martin van den Bent, President of European Association of Neuro-Oncology. “He brings tremendous energy and a commitment to build upon the strong foundation established by Dr. Chang.”

Dr. Taphoorn will draw on the experience of a 30-plus year career devoted to neuro-oncology research in his role at the helm of Neuro-Oncology Practice. He has previously served as an Associate Editor of Neuro-Oncology Practice, and currently serves of the Editorial Board of Neuro-Oncology and is on the International Advisory Board for Lancet Oncology.

Outgoing Editor-in-Chief, Susan Chang, offered her thoughts on the journal saying “launching Neuro-Oncology Practice has been one of the highlights of my professional and academic career. I am grateful for the tremendous support of my Executive Editors representing the European, Asian and North American societies respectively: Drs. Wolfgang Griesold, Rakesh Jalali, and Jeffrey Wefel.” With regard to the journal's future, Dr. Chang commented, “I am thrilled with Dr. Taphoorn’s appointment, and have every confidence he will guide the journal to new heights.”

Neuro-Oncology Practice was made possible through a seed grant from the National Brain Tumor Society, with the goal of providing a platform for practical and applied content for those on the front lines of brain tumor treatment. The journal provides the multidisciplinary field of neuro-oncology professionals -- including physicians, nurses, physical and occupational therapists, palliative care specialists, and neuropsychologists -- with clinical information to enhance patient care, quality of life, psycho-social support, and management of co-morbid conditions.

Chas Haynes, Executive Director of SNO commented, “As a joint venture between SNO, EANO and Oxford University Press, the success of the journal clearly demonstrates the value of our organizations working together to advance our field. I have no doubt this will lead to new opportunities for our respective organizations to collaborate.”

Dr. Taphoorn’s seven-year term as Editor-in-Chief of Neuro-Oncology Practice will begin January 1, 2021. Elizabeth Martinson, will remain in her role as Managing Editor from her office in Frankfurt, Germany.

To view the Neuro-Oncology Practice website, click here.
2020 SNO Committees

Audit Committee
Chair: James Perry

Awards Committee
Co-Chairs: Daphne Haas-Kogan, Susan Chang
Eva Galanis

Bylaws Committee
Chair: Jeffrey Wefel

Communications Committee
Co-Chairs: Alireza Mansouri, Jennie Taylor

Education Committee
Co-Chairs: Patrick Wen, Isabel Arrillaga-Romary

Fellowship Match Committee
Co-Chairs: Maciej Mrugala, Leila Nghiemphu, Scott Plotkin

Future Sites Committee
Presently inactive

Guidelines and Reported Outcomes Committee
Co-Chairs: Burt Nabors, Jana Portnow

International Outreach Committee
Co-Chairs: James Balogun, Zarnie Lwin, Edjah Ndoum

External Relations Committee
Co-Chairs: Erin Dunbar, Vinay Puduvalli

Membership Committee
Co-Chairs: Rohan Ramakrishna, Sameer Agnihotri
John de Groot, Alissa Thomas

Public Policy Committee
Co-Chairs: Antonio Chiocca, Raymond Sawaya

Website and Technology Committee
Chair: Erik Sulman

Wellness Committee
Co-Chairs: Alvina Acquaye, Terri Armstrong, Shlomit Yust-Katz

Women and Diversity Committee
Co-Chairs: Shawn Hervey-Jumper, Ugonma Chukwueke,
Alyx Porter Umphrey

Young Investigators Committee
Co-Chairs: Milan Chheda, Jennifer Moliterno Gunel, Eudocia Lee

Society for Neuro-Oncology
PO Box 273296
Houston, TX 77277-3296
www.soc-neuro-onc.org
office@soc-neuro-onc.org
(713) 526-0269

SNO Leadership

SNO Officers
President: Gelareh Zadeh
Vice President: Tracy Batchelor
Secretary-Treasurer: Erik Sulman
Executive Director: Charles Haynes

SNO Board of Directors
Sue Bell, Allied Health
Gavin Dunn, Young Investigators
Jason Huse, Pathology
Nicholas Butowski, Neuro-Oncology
Ian Dunn, Neurosurgery
Annette Molinaro, Other Specialties
Michelle Monje, Pediatrics
Raymond Huang, Radiology
Solmaz Sahebjam, Medical Oncology
Jennifer Yu, Radiation Oncology
Michael Taylor, Basic Science

Past President: Patrick Wen

SNO Foundation
Mitchel S. Berger
E. Antonio Chiocca
Victor A. Levin (Society Founder)
Susan Chang
David Reardon

SNO Publications
Neuro-Oncology
Editor-in-Chief Kenneth Aldape
SNO Editor Patrick Wen

Neuro-Oncology Practice
Editor-in-Chief Susan Chang
SNO Editor Jeffrey Wefel

Neuro-Oncology Advances
Editor-in-Chief Gelareh Zadeh

SNO News
The SNO News is published two times per year
and is distributed to members and friends of
the Society for Neuro-Oncology.

Editors: Jennie Taylor, Alireza Mansouri
SNO Communications Chairs
Associate Editor: Chas Haynes
Society for Neuro-Oncology
© Society for Neuro-Oncology 2020

Page 10